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Lay summary
Excess liver iron content is common and
is associated with liver diseases and
metabolic diseases including diabetes,
high blood pressure, and heart disease.
We identified 3 genetic variants that are
linked to an increased risk of developing
higher liver iron content. We show that
the same genetic variants are linked to
higher risk of many diseases, but they
may also be associated with some health
advantages. Finally, we use genetic vari-
ants associated with waist-to-hip ratio as
a tool to show that central obesity is
causally associated with increased liver
iron content.Genetic and Metabolic Diseasesis is an open access article under the CCBY license (http://
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Background & Aims: Excess liver iron content is common and
is linked to the risk of hepatic and extrahepatic diseases. We
aimed to identify genetic variants influencing liver iron content
and use genetics to understand its link to other traits and
diseases.
Methods: First, we performed a genome-wide association study
(GWAS) in 8,289 individuals from UK Biobank, whose liver iron
level had been quantified by magnetic resonance imaging,
before validating our findings in an independent cohort
(n = 1,513 from IMI DIRECT). Second, we used Mendelian ran-
domisation to test the causal effects of 25 predominantly meta-
bolic traits on liver iron content. Third, we tested phenome-
wide associations between liver iron variants and 770 traits
and disease outcomes.
Results:We identified 3 independent genetic variants
(rs1800562 [C282Y] and rs1799945 [H63D] in HFE and
rs855791 [V736A] in TMPRSS6) associated with liver iron con-
tent that reached the GWAS significance threshold
(p <5  108). The 2 HFE variants account for 85% of all cases
of hereditary haemochromatosis. Mendelian randomisation
analysis provided evidence that higher central obesity plays a
causal role in increased liver iron content. Phenome-wide asso-
ciation analysis demonstrated shared aetiopathogenic mecha-
nisms for elevated liver iron, high blood pressure, cirrhosis,
malignancies, neuropsychiatric and rheumatological conditions,
while also highlighting inverse associations with anaemias,
lipidaemias and ischaemic heart disease.
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Conclusion: Our study provides genetic evidence that mecha-
nisms underlying higher liver iron content are likely systemic
rather than organ specific, that higher central obesity is causally
associated with higher liver iron, and that liver iron shares com-
mon aetiology with multiple metabolic and non-metabolic
diseases.
Lay summary: Excess liver iron content is common and is asso-
ciated with liver diseases and metabolic diseases including dia-
betes, high blood pressure, and heart disease. We identified 3
genetic variants that are linked to an increased risk of develop-
ing higher liver iron content. We show that the same genetic
variants are linked to higher risk of many diseases, but they
may also be associated with some health advantages. Finally,
we use genetic variants associated with waist-to-hip ratio as a
tool to show that central obesity is causally associated with
increased liver iron content.
 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Liver disease constitutes the third most common cause of pre-
mature death in the UK, and its prevalence is substantially
higher compared to other countries in Western Europe.1–3
Excess liver iron is associated with increased severity and pro-
gression of liver diseases including cirrhosis and hepatocellular
carcinoma in individuals with non-alcoholic fatty liver disease
(NAFLD),4–6 and is the direct cause of liver disease in those with
hereditary haemochromatosis and thalassaemia.7,8 Observa-
tional associations have been described between excess liver
iron content and several metabolic diseases such as high blood
pressure, obesity, polycystic ovarian syndrome and type 2 dia-
betes, in a condition recognised as dysmetabolic iron overload
syndrome (DIOS) which affects up to 5–10% of the general
population.9,10
The associations between excess liver iron and hepatic and
non-hepatic diseases necessitate exploration of underlying
pathophysiological mechanisms. Studies of patients with019 vol. 71 j 594–602
mass index (BMI) or alcohol consumption in our sensitivity
analysis. We then performed inverse normal transformation
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tions, show they have higher liver iron, measured from biopsies,
when compared to controls. However, no studies have been per-
formed in unselected populations. Furthermore, it is unknown
whether iron accumulation is a systemic disorder involving
multiple organs or whether there are mechanisms specific to
the liver. Previous genome-wide association studies (GWAS)
have focussed on peripheral biochemical markers of iron status
that do not correlate well with liver iron.11
Measuring liver iron has traditionally been difficult. Liver
biopsy, the ‘‘gold standard” for assessment of liver iron, is an
invasive procedure and therefore unsuitable for population
research studies. An alternative is magnetic resonance imaging
(MRI); a non-invasive, quick, robust and validated method for
quantifying liver iron content.12 The availability of genetic and
clinical data, as well as MRI scans of livers in the UK Biobank
cohort has provided an unparalleled opportunity to study the
genetics of liver iron content in a population-based cohort.
The aim of this study was to (i) identify genetic variants
specifically associated with liver iron content, (ii) investigate
which metabolic traits and diseases might cause higher liver
iron content, and (iii) characterise the traits/diseases associated
with liver iron content susceptibility variants. To facilitate this,
we performed the first GWAS of MRI-determined liver iron con-
tent in 8,289 UK Biobank participants and replicated our find-
ings in an independent cohort of 1,513 participants of
European ancestry from the IMI DIRECT study (Fig. 1).13,14
Patients and methods
UK Biobank participants
The UK Biobank consists of over 500,000 individuals aged 37–
73 years (99.5% were between 40 and 69 years of age) who were
recruited between 2006 and 2010 from across the UK.13 This
research has been conducted using the data obtained via UK
Biobank Access Application number 9914. UK Biobank field
numbers used for this analysis can be found in Table S1. We
used data from the first subset of UK Biobank participants
invited for multiparametric MRI imaging between 2014 and
2016.15 After image analysis and quality control steps (see
below), liver iron was available for 8,674 individuals who also
had genetic data. We based our study on 8,289 individuals of
white European descent as defined by principal component
(PC) analysis.
Stage 1: Discovery 
Identification of loci of interest associated 
with liver iron in UK Biobank (N = 8,289) 
Around 12 million imputed SNPs 
4 independant variants (p <5x10-8)
Stage 2: Replication 
3 variants replicated in DIRECT (N = 1,513) 
(p <4x10-4)
Gene prioritisation, 
tissue and 
pathway analysis
Heritability, 
LD regression
Mendelian 
Randomisation, 
PheWAS
Fig. 1. Study design. GWAS on liver iron content was performed in UK
Biobank (N = 8,289) and replicated in IMI DIRECT (N = 1,115). GWAS, genome-
wide association study; SNPs, single-nucleotide polymorphisms.Journal of Hepatology 2Genetic data
Protocols for the participant genotyping, data collection, and
quality control have previously been described in detail.13
Briefly, participants were genotyped using 1 of 2 purpose-
designed arrays (UK BiLEVE Axiom Array (n = 50,520) and UK
Biobank Axiom Array (n = 438,692)) with 95% marker overlap.
We excluded individuals who were identified by the UK Biobank
as outliers based on either genotyping missingness rate or
heterogeneity, or whose sex inferred from the genotypes did
not match their self-reported sex. We removed individuals with
a missingness >5% across variants which passed our quality con-
trol procedure. We used the latest release which included
imputed data using 2 reference panels: a combined UK10K
and 1000 Genomes panel and the Haplotype Reference Consor-
tium panel. We limited our analysis to genetic variants with a
minimum minor allele frequency (MAF) >1% and imputation
quality score (INFO) >0.3.
Imaging protocol and analysis
The imaging protocol and analysis of liver iron content in UK
Biobank participants has previously been published.15 Briefly,
participants were scanned at the UK Biobank centre in Cheadle
(UK) using a Siemens 1.5 T Magnetom Aera. A single-breath-
hold MRI sequence was acquired as a single transverse slice
captured through the centre of the liver, superior to the porta
hepatis. This sequence forms part of the UK Biobank abdominal
imaging protocol. The data were analysed using the LiverMultiS-
canTM Discover software (version 4.0; Perspectum Diagnostics
Ltd, UK) by a team of trained analysts, blinded to any subject
variables. Analysts selected three 15 mm diameter circular
regions of interests, to cover a representative sample of the liver
parenchyma, avoiding vessels, bile ducts and other organs. The
repeatability and reproducibility of the image analysis was
high.15
Genome-wide association analysis
We performed the association tests using 2 different software:
(1) GEMMA version 0.96 as our main analysis using all individ-
uals of genetically defined Europeans (n = 8,289),16 and (2)
PLINK version 1.9 as our sensitivity analysis using unrelated
white British individuals (defined in UK Biobank field 22,006,
n = 6,758).17
GEMMA applies a linear mixed-model to adjust for the
effects of population structure and relatedness. Therefore, we
increased our power by including all related individuals of Euro-
pean descent. The relatedness matrix was computed using com-
mon (MAF >5%) genotyped variants that passed quality control.
Prior to association testing, liver iron was first log-transformed
and then adjusted for age, sex and study centre, as well as bodyon the values. At runtime, we included genotyping array (as a
categorical variable for UKBileve array, UKB Axiom array
interim release and UKB Axiom array full release) as a covariate.
We used PLINK to perform a sensitivity analysis. Prior to
association testing, liver iron was adjusted for age, sex, BMI
and genotyping array, and then we quantile normalised the
resulting values. At runtime, we included the first 10 genetic
PCs (UK Biobank field 22,009) as covariates to control for con-
founding by population stratification. We used Quanto (http://
biostats.usc.edu/Quanto.html) to calculate our discovery GWAS
power in 8,289 individuals from the UK Biobank at different019 vol. 71 j 594–602 595
allele frequencies and effect sizes at a level 5  108 assuming
additive effect model (Fig. S1).
Linkage disequilibrium score regression and cross-trait
genetic correlation analysis
We used LDHub to conduct linkage disequilibrium (LD) score
regression and heritability analysis. LD Hub is a centralized data-
base of summary level GWAS for >100 diseases/traits from pub-
licly available resources/consortia and uses a web interface that
automates LD score regression, heritability and cross-trait
genetic correlation analysis pipeline.18 We ran heritability anal-
ysis as well as genetic correlation analysis across 448 potentially
relevant traits. SNP-based heritability (h2SNP) is the proportion of
was responsible for any of the individual variant associations
and replicate GEMMA results, we ran a GWAS using only unre-
lated Europeans individuals in the UK Biobank and a different
GWAS software tool (PLINK version 1.9). Third, we adjusted
models for alcohol intake frequency (field 1,558; categories trea-
ted as ordinal scale – ‘‘Never” = 0 to ‘‘Daily or almost daily” = 5)
measured at baseline that may have had an impact on liver iron.
Individuals responding ‘‘Do not know” or ‘‘Prefer not to answer”
for ‘‘Alcohol intake frequency” were excluded from this sensitiv-
ity analysis. Fourth, to investigate the potential for collider bias
resulting from conditioning liver iron on BMI, we performed a
GWAS of liver iron without adjustment for BMI.
Research Article Genetic and Metabolic Diseasestotal variation in liver iron content due to the additive genetic
variation between individuals in our study population.
Gene-set and tissue expression enrichment analysis
We performed gene-set and tissue expression analyses using
MAGMA.19 Lead variants were assigned to a minimum p value
of 5  108. We used the default settings provided by the soft-
ware. We chose 1000 Genomes Phase 3 as the reference panel
population. The minimum minor allele frequency was set to
1%. We used a maximum allowed distance of 250 kb between
LD blocks for variants to be included in the same locus.
For gene-set enrichment analyses, positional mapping was
used with variants assigned to a gene if they were within the
gene start and end points (by setting the distance either side
to 0 kb). Only protein-coding genes were included in the map-
ping process. Tested gene sets include BioCarta, REACTOME,
KEGG and GO. Bonferroni correction was used to adjust for the
number of gene sets tested. Analysis of differentially expressed
genes was based on data from GTEx v6 RNA-seq data.20
Replication analysis
Associations reaching p <5  108 were followed up in the IMI
DIRECT cohort. IMI DIRECT includes 1,513 participants who
had both liver iron and GWAS data to replicate our findings.
The IMI DIRECT consortium is a collaboration among investiga-
tors from a range of European academic institutions and phar-
maceutical companies.14 Liver iron was measured using a T2*-
based multi-echo MRI technique.21 DNA extraction was carried
out using Maxwell 16 Blood DNA purification kits and a Max-
well 16 semi-automated nucleic acid purification system (Pro-
mega). Genotyping was conducted using the Illumina
HumanCore array (HCE24 v1.0) and genotypes were called
using Illumina’s GenCall algorithm. A total of 517,958 markers
passed quality control procedures. We took autosomal variants
with MAF >1% that passed quality control and constructed axes
of genetic variation using PC analysis implemented in the GCTA
software to identify ethnic outliers defined as non-European
ancestry using the 1000 Genomes samples as reference. We
identified 6 individuals as ethnic outliers.
We performed the association tests in 3 models: (i) non-
diabetic participants (n = 1,010), (ii) diabetic participants
(n = 503), and (iii) combined (n = 1,513). We took residuals from
a model of liver iron and age, sex, BMI, 10 PCs and centres,
before performing inverse normal transformation on the values.
Sensitivity analyses
We performed 4 sensitivity analyses. First, to assess whether
there is any sex-specific association, we carried out GWASs in
men and women separately. Second, to test whether relatedness
596 Journal of Hepatology 2Mendelian randomisation
Multiple traits have shown association with liver iron in obser-
vational studies, including BMI, lipids and non-alcoholic fatty
liver disease.10,22–24 We therefore investigated the causal effects
of 25 predominantly metabolic traits using 2-sample Mendelian
randomisation analysis.25 Mendelian randomisation is a method
that uses genetic variants associated with the exposure (e.g.
metabolic traits) to infer causal relationships between an expo-
sure and an outcome (e.g. liver iron content). This method relies
on a simple principle; if a modifiable exposure is causal for a
disease, then the genetic variants associated with that exposure
will also be associated with disease risk. Since genetic variants
are inherited at birth, Mendelian randomisation experiments
are free from confounding and biases that are seen in observa-
tional studies.
Following correction for multiple testing, associations with a
false discovery rate (FDR) <5% were considered statistically sig-
nificant. We used the inverse variance weighted approach (IVW)
as our main analysis, and MR-Egger and penalised weighted
median as sensitivity analyses in the event of unidentified pleio-
tropy of our genetic instruments. Genetic instruments for the 25
metabolic traits as an exposure were constructed by developing
risk scores using only genome-wide significant SNPs that were
not in LD (R2 <0.1).26–28
Phenome-wide association study
We used the SNPs associated with liver iron content and carried
out a phenome-wide association study (PheWAS) using publicly
available summary statistics from GWASs on predefined ICD10
disease codes, anthropometric traits, and self-reported condi-
tions previously carried out in 452,264 UK Biobank participants
of European ancestry,29 as well as publicly available, curated
summary statistics from previous GWAS (Tables S2–4).30 Asso-
ciations with an FDR <5% were considered statistically signifi-
cant. A description of how ICD codes were grouped to
represent a clinical phenotype are provided elsewhere.29
Results
The characteristics of liver iron content cohort
The median liver iron content in the UK Biobank was 1.28 mg/g
(interquartile range [IQR] 1.16–1.44 mg/g) in men (n = 3,928)
and 1.23 mg/g (IQR 1.13–1.38) in women (n = 4,361) (Table 1,
Fig. S2). In this cohort, 6.5% of men and 3.4% of women had an
elevated liver iron content, above the commonly accepted
1.8 mg/g threshold.31 In the IMI DIRECT cohort, the median liver
iron content was 1.3 (1.2–1.5) in both men (n = 1,101) and
women (n = 412). BMI, waist circumference and diabetes preva-
lence were lower in the liver iron cohort (n = 8,289) than the
019 vol. 71 j 594–602
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OF HEPATOLOGYremainder of the UK Biobank (n = 402,071) (Table S5). Although
invitation was not based on any medical information, MRI
exclusion criteria (e.g. metal or electrical implants, surgery
6 weeks prior to appointment, severe hearing or breathing prob-
lems) may have also contributed to a slightly healthier cohort.
The Townsend deprivation index was on average lower in this
study cohort. This may be related to MRI participants being
biased towards those who live close to the imaging centre
(Cheadle) where all of the liver iron cohort were imaged.
There are 3 genetic variants associated with liver iron
content
We performed a GWAS of MRI-derived measures of liver iron
content using 8,289 individuals of European ancestry from the
UK Biobank (Fig. 2, Fig. S3). We estimated to have more than
80% power in our discovery set to detect variants with MAF
≥5% and effect size ≥0.2 standard deviation (SD) on liver iron
Table 1. Characteristics of participants in the UK Biobank and IMI DIRECT
Characteristics UK Biobank liver i
Men
N (%) 3,928
Age, years (IQR) 57 (51–62)
Liver iron, mg/g (IQR) 1.28 (1.16–1.44)
Waist circumference, cm (IQR) 94 (88–101)
Townsend deprivation index (IQR) 2.72 (-3.95 to 0.76)
Self-reported diabetes (%) 134 (3.7%)
BMI, kg/m2 (IQR) 26.49 (24.3–29)
No consuming alcohol daily (%) 1,088 (27.7%)
BMI, body mass index; IQR, interquartile range; n.a., not available.
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Fig. 2. Manhattan plot illustrating genetic variants associated with liver iron
the association with each variant. The black line indicates genome-wide signific
Table 2. Genome-wide significant independent variants associated with MRI l
UK Bioba
(N = 8,28
SNP Gene Chr EA OA EAF BETA SE
rs1800562 HFE 6 A G 0.08 0.41 0.03
rs1799945 HFE 6 G C 0.15 0.16 0.02
rs855791 TMPRSS6 22 G A 0.56 0.11 0.02
rs149275125 HS3ST3B1/
PMP22
17 C T 0.98 0.41 0.07
Beta, per allele effect on liver iron (SD); Chr, chromosome; EA, effect allele; EAF, e
polymorphism.
* Data from The Genome Aggregation Database (gnomAD; https://gnomad.broadinstit
Journal of Hepatology 2content (Fig. S1). We detected no evidence of test-statistic
inflation (kGC = 1.016). Our discovery GWAS identified 4 inde-
pendent variants at p <5  108 (Table 2). Two independent
variants lie within HFE: C282Y (rs1800562; 0.41 SD increase
in liver iron per allele; p = 5.2  1042) and H63D (rs1799945;
0.17 SD; p = 8.2  1015). The third variant lies in TMPRSS6;
V736A (rs855791; 0.11 SD; p = 1.3  1011). The fourth variant,
rs149275125, lies between HS3ST3B1 and PMP22 (0.41 SD;
p = 3  109).
In 1,513 IMI DIRECT participants, we replicated all 3 common
variants at p <4  104 with a consistent direction of effect and
similar effect size (Table S6). The fourth variant, rs149275125,
did not associate with liver iron in IMI DIRECT and the direction
of effect was opposite to our discovery dataset. This variant is a
rare variant (MAF 1%) and has not previously been reported to
be associated with any other traits. We focussed all other anal-
yses on the 3 replicated variants.
udy.
n cohort IMI DIRECT
Women Men Women
4,361 1,101 412
56 (49–61) 62 (56–66) 62 (57–67)
1.23 (1.13–1.38) 1.3 (1.2–1.5) 1.3 (1.2–1.5)
80 (74–89) 101 (95–109) 97 (88–108)
2.63 (-3.87 to 0.80) n.a n.a.
88 (2.2%) 287 (26%) 216 (52.4%)
25.08 (22.59–28.35) 27.8 (25.8–30.5) 28.7 (25.8–33.2)
825 (18.9%) 129 (15.6%) 25 (10.7%)
8 9 10 11 12 13 14 16 18 20 22
in UK Biobank. The x-axis is the chromosomal position and y axis is -log(P) for
ance level (5  108). SNPs, single-nucleotide polymorphisms.
iver iron content in UK Biobank (p <5  108) and validation in IMI DIRECT.
nk
9)
IMI DIRECT
(N = 1,513)
Non-Finnish
Europeans*
p value EAF BETA SE p value EAF
5.2  1042 0.04 0.35 0.08 5  105 0.06
8.2  1015 0.12 0.19 0.05 2  104 0.14
1.3  1011 0.59 0.12 0.04 4  104 0.56
3.1  109 0.99 0.22 0.2 0.27 0.99
ffect allele frequency; OA, other allele; SE, standard error, SNP, single nucleotide
ute.org).019 vol. 71 j 594–602 597
Both HFE and TMPRSS6 produce proteins that form part of the
signalling pathway regulating hepcidin production, the key hor-
mone responsible for iron balance in the body. C282Y homozy-
gotes and C282Y/H63D compound heterozygotes account for
85% of cases of hereditary haemochromatosis.7 In the UK Bio-
bank, 35 individuals (0.4%) were C282Y homozygotes and had
the highest levels of liver iron (mean 2.39 mg/g [±1.2]); 182
(2.2%) were C282Y/H63D compound heterozygotes (1.75 mg/g
[±0.7]); 186 (2.2%) were H63D homozygotes (1.46 mg/g
[±0.47]); 2,920 (35%) were either C282Y or H63D heterozygotes
(1.34 mg/g [±0.32]); 4,966 (60%) did not have any of the variants
and had the lowest liver iron (1.28 mg/g [±0.24]) (Fig. 3).
Correlation between the effect sizes and p values in the 2
separate GWASs carried out in GEMMA and PLINK showed
strong agreement (Figs. S4 and S5). We did not detect any
sex-specific variants and the magnitude of effect was similar
between men and women (Table S6, Fig. S6). The sensitivity
analysis adjusting for alcohol consumption and BMI did not
identify any additional signal and did not change the effect size
(Table S6). Our pathway analysis demonstrates overlap between
liver iron gene sets and pathways involved in autism and
schizophrenia (Fig. S7). Nearby genes were visualised with
LocusZoom plots (Figs. S8 and S9).
Liver iron content is heritable and has a high genetic
correlation with blood levels of iron biomarkers
We estimated the SNP-based heritability (h2SNP) of liver iron to
be 7%. This is similar to heritability estimated for conditions
and traits such as coronary artery disease (7%)32 and eczema
(7%),33 but lower than heritability estimated for body fat %
(10%)34 and transferrin (16%).11
To identify genetic overlap between liver iron content and
other diseases and traits, we performed LD score regression
analyses against a range of available traits and diseases with
GWAS summary statistics (448 traits/diseases, Table S7). The
most genetically correlated traits were transferrin (rG = 0.78,
p = 0.04) and ferritin (rG = 1.24, p = 0.05) with nominal signifi-
cant correlation. Joint disorders (rG = 1.17, p = 0.50), hyper-
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Fig. 3. Liver iron content per genotype group. The x-axis represents the 6
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axis represents the mean of liver iron (mg/g) per category. Error bars indicate
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598 Journal of Hepatology 2trophic cardiomyopathy (rG = 1.11, p = 0.35), type 2 diabetes
(rG = 0.44, p = 0.17), chronic kidney disease (rG = 0.57, p = 0.48),
tinnitus (rG = 0.65, p = 0.17), polyuria (rG = 0.75, p = 0.36), and
gout (rG = 0.90, p = 0.19) were highly correlated (rG >0.4) but
did not reach a nominal significance threshold (p >0.05). Meta-
bolic traits including fasting insulin (rG = 0.17, p = 0.53), homeo-
static model assessment of insulin resistance (rG = 0.37,
p = 0.48), fasting glucose (rG = 0.01, p = 0.97) and coronary
artery disease (rG = 0.01, p = 0.97) were not genetically corre-
lated with liver iron content.
Gene-set enrichment analysis did not identify any enriched
tissue or pathways
We used MAGMA implemented as part of the FUMA GWAS plat-
form to assess tissue enrichment of genes at associated loci. We
did not find any tissue enrichment, but differentially expressed
gene sets were enriched in blood vessels, lung, and adipose tis-
sue, although they did not reach a significant threshold follow-
ing adjustment for multiple testing (Table S8). None of the
pathways reached our FDR significance threshold (Table S9).
Mendelian randomisation analysis provides evidence for a
causal link between central obesity and liver iron content
We examined the potential causal effect of 25 metabolic traits
and diseases (Fig. 4, Table S10) on liver iron content. Following
correction for multiple testing (FDR <5%), we found evidence of
a causative effect of central obesity, as measured by higher
waist-to-hip ratio (adjusted for BMI), on elevated liver iron con-
tent (IVW p = 0.003) (Table S9, Fig. S10). There was suggestive
evidence that higher fasting glucose (IVW p = 0.03), higher
NAFLD (IVW p = 0.04) and higher alanine aminotransferase
(IVW p = 0.05) were causally associated with higher liver iron
content, but none of these associations reached our multiple
testing threshold of being statistically significant. All the results
were robust to a range of Mendelian randomisation sensitivity
analyses.
As a positive control, elevated transferrin saturation levels
(IVW p = 0.0007), blood iron content (IVW p = 0.01) and ferritin
levels (IVW p = 0.01) were associated with higher liver iron con-
tent. The genetic variants (between 5 to 6 variants) associated
with these serum iron parameters include the 3 variants associ-
ated with liver iron content (HFE C282Y, HFE H63D, TMPRSS6
V736A). Therefore, it was not possible to test the causal effect
of these parameters on liver iron content independently of
HFE and TMPRSS6 genetic variants.
PheWAS identifies novel associations of liver iron variants
with traits and diseases
The 3 liver iron content variants had previously been reported
to be associated with multiple haematological parameters, gly-
cated haemoglobin, lipid and bilirubin levels, as well as blood
pressure traits (Table S11). We performed a hypothesis-free
PheWAS to investigate the association of these 3 variants with
other traits and diseases using predefined ICD10 codes, self-
reported conditions and traits from the UK Biobank and publicly
available GWAS.
HFE C282Y was associated with higher liver fibrosis/cirrho-
sis, higher risk of type 2 diabetes, hypertension, alcohol-
related liver disease, arthrosis, chronic and degenerative neuro-
logical conditions including multiple sclerosis, arthritis and
higher height but lower total cholesterol, lower low-density
lipoprotein cholesterol (LDL-C) and lower BMI (FDR <5%,
019 vol. 71 j 594–602
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Fig. 4. The effect of 25 predominantly metabolic traits and diseases on
liver iron content. The plot illustrates per allele effect of genetic variants
associated with different metabolic traits. We have used alleles associated
with higher adiposity, higher metabolic disease risk, higher glycaemic traits,
adverse lipid levels, higher liver enzymes and adverse metabolic biomarkers
profile. For comparison, the plot illustrates the effect of HFE C282Y, HFE H63D,
TMPRSS6 V736A on liver iron content. Please refer to Table S10 for the results
of 2-sample Mendelian randomisation analysis including 4 circulating iron
biomarkers. The error bars indicate 95% CIs. ALP, alkaline phosphatase; ALT,
alanine aminotransferase; BMI, body mass index; CRP, C-reactive protein;
GGT, gamma-glutamyltransferase; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; NAFLD, non-alcoholic fatty liver disease; SHBG, sex
hormone binding globulin. The statistical test illustrated on x-vector is from
the Inverse Variance Weighted (IVW) method.
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Fig. 5. Illustration of prioritised associations following phenome-wide asso
Data from the UK Biobank and publicly available summary statistics. Blue indi
for multiple testing (false discovery rate <5%). Continuous traits betas were sca
given in log(odds ratio). BMI, body mass index; LDL, low-density lipoprotein.Journal of Hepatology 2Fig. 5, Table S2). HFE H63D was associated with higher risk of
hypertension, ankylosing spondylitis and bladder malignancy
but lower risk of malabsorption or coeliac disease and lower
cognitive ability (FDR <5%, Fig. 5, Table S3). The liver iron
increasing allele at TMPRSS6 was associated with lower risk of
ischaemic heart disease, angina pectoris, and lipidaemias (FDR
<5%, Fig. 5, Table S4).
Discussion
We performed the first GWAS of multiparametric MRI-
determined liver iron content in an unselected population. The
identification of loci implicated in increased iron absorption
(HFE and TMPRSS6) provides genetic validation of the utility of
MRI for the non-invasive assessment of liver iron content.
The 3 independent variants in HFE and TMPRSS6 have previ-
ously been reported to be associated with circulating iron traits
including transferrin saturation, blood iron, ferritin, and trans-
ferrin levels.11 Both HFE and TMPRSS6 play a major role in iron
homeostasis by modulating the expression of hepcidin produc-
tion by the liver.35,36 Hepcidin inhibits iron transport and
absorption from the gut into the circulation by binding to the
main iron transport channel expressed on the surface of duode-
nal enterocytes, ferroportin.37 TMPRSS6 encodes matriptase 2
(MTP-2), a liver serine protease, which inhibits hepcidin leading
to higher iron absorption and bioavailability. In vitro studies
have shown that major allele at rs888571 inhibits hepcidin
more effectively than the missense variant rs888571
(V736A).38 HFE is a positive upstream regulator of hepcidin
transcription. Missense variants C282Y and H63D in HFE result
in lower hepcidin responsiveness to iron, leading to relative or
absolute hepcidin deficiency and subsequent increases in iron
absorption and bioavailability.39
Elevated liver iron is observationally associated with multi-
ple metabolic traits and diseases in a common condition
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Research Article Genetic and Metabolic Diseasesdescribed as DIOS.10 Our Mendelian randomisation analysis
supports a causal role for higher central obesity on higher liver
iron content, providing further evidence for DIOS. Other traits
such as fasting glucose, NAFLD, and alanine aminotransferase
showed suggestive causal associations. Animal studies have
suggested a putative mechanism of defective iron handling
and subsequent iron overload caused by an inflammatory shift
and cytokine secretion by activated macrophages that accumu-
late around adipocytes in obesity.40,41 The underlying mecha-
nism, however, is still unclear, and is likely to involve a
complex interplay between diet and genetic factors, as well as
cross-talk between the liver and visceral adipose tissue.10
Our GWAS study identified variants that are likely to regu-
late iron stores systemically and are not specific to the liver.
Therefore, we were not able to examine the causal role of higher
associated with lower LDL-C, lower risk of angina and ischaemic
heart disease. Similar observations have been reported in HFE
driven through effects on haematological parameters, or lowerliver iron content per se on other diseases and traits using Men-
delian randomisation. To investigate the phenotypic architec-
ture and shared pathological mechanisms of higher liver iron
content with other traits and diseases, we carried out a PheWAS
of the 3 genome-wide significant variants against all available
disease outcomes and traits from the UK Biobank29 and publicly
available genetic summary statistics.30
Our PheWAS indicates HFE C282Y is associated with arthro-
sis, coxarthrosis, osteoarthritis, and gout, and HFE H63D is asso-
ciated with ankylosing spondylitis and has a suggestive
association with dorsalgia. The association between HFE
C282Y and higher risk of cellulitis, abscesses, furuncles and cur-
buncles, subcutaneous infections as well as osteomyelitis pro-
vides further evidence that genetically elevated iron levels are
associated with higher infection risk. Some infectious disease
agents are more virulent in an environment with excess iron.
There is also evidence that iron overload compromises the abil-
ity of phagocytes to kill microorganisms.42
43Higher iron is correlated with carcinogenesis. An important
mechanism may be oxidative stress and the catalytic activity of
iron in the formation of hydroxyl radicals. Iron may also sup-
press host defences and promote cancer cell proliferation. A
recent study found an association between HFE C282Y and a
higher risk of breast cancer, colorectal cancer, hepatocellular
carcinoma, and total cancer.44 We found additional evidence
of associations with extrahepatic malignancies including blad-
der cancer (odds ratio 1.0004 per copy of H63D,
p = 4.7  106, FDR 0.03) and renal cancer (odds ratio 1.0005
per copy of C282Y, p = 0.004, FDR 0.05). Despite very small
effects, these findings provide genetic evidence for shared
mechanisms underlying higher liver iron and extrahepatic
cancers.
The association between HFE C282Y and neurological condi-
tions such as multiple sclerosis and epilepsy is consistent with
the role of iron in many important processes in the central ner-
vous system, including oxygen transportation, oxidative phos-
phorylation, myelin production, and the synthesis and
metabolism of neurotransmitters. In a recent GWAS of brain
MRI scans, HFE C282Y was associated with iron accumulation
in certain parts of the brain.45 Observational studies show that
iron accumulation in the brain is associated with multiple scle-
rosis, parkinsonism and Alzheimer’s disease.46,47 Individuals
with hereditary haemochromatosis frequently develop psycho-
logical symptoms, including extreme fatigue, irritability and
depression.48 Our pathway analysis demonstrates overlap with
gene sets and pathways involved in autism and schizophrenia.
HFE H63D was associated with a reduction in reaction time in600 Journal of Hepatology 2specific cognitive function tests, providing further evidence that
iron accumulation may cause premature, and indeed pre-
ventable, cognitive decline.
The association between HFE variants and hypertension is
consistent with previous findings.49 Possible mechanisms
include increased vascular tone secondary to the generation of
reactive oxygen species and oxidative stress,50 or excess iron
accumulation in renal arterioles leading to activation of the
renin-angiotensin aldosterone system. We further validated
the known association between HFE C282Y and type 2 diabetes
which could be, at least partly, due to iron accumulation in the
pancreas.
The liver iron increasing allele at TMPRSS6 rs855791 wasC282Y homozygotes.51 A Mendelian randomisation study has
recently reported that elevated circulating iron may have a cau-
sal (protective) effect on coronary artery disease.52 The underly-
ing mechanism is unclear. It is possible that part of this effect isLDL-C. In conditions where excess iron stores are treated (e.g.
hereditary haemochromatosis), further research is needed on
whether LDL-C levels subsequently increase, and whether the
risk of coronary artery disease can be kept low with statins
and other preventive interventions.51
This study is limited in that the UK Biobank MRI cohort is not
a completely unbiased sample of the population. The UK Bio-
bank MRI cohort is slightly more healthy, wealthy, and well
educated than the whole cohort of 40–69 year olds in the
UK.53 The population studied in this work has a slightly lower
average BMI and waist circumference than the UK Biobank pop-
ulation as a whole. Larger GWAS studies (e.g. on completion of
the full 100,000 UK Biobank imaging cohort) may elucidate fur-
ther susceptibility loci. Ongoing development and validation of
MRI scores that may allow accurate determination of the level
of inflammation and fibrosis, may lead to further genetic studies
focussing on the more severe spectrum of liver disease.
Conclusion
We performed a large GWAS of MRI liver iron content and iden-
tified 3 susceptibility loci previously linked with circulating iron
traits. We provided genetic validation for multiparametric MRI
as a novel, non-invasive and radiation free imaging modality
for liver iron content. Our genetic study suggests that higher
liver iron content may be caused in part by higher central adi-
posity. The deposition of excess iron in the liver seems to share
commonmechanisms with circulating iron accumulation, which
eventually results in widespread damage to parenchymal tissue,
leading to several pathologies through a common mechanism.
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